Repligen Stock Price, News & Analysis (NASDAQ:RGEN)

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last twelve months. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RGEN shares.
View RGEN analyst ratings or view top-rated stocks.

11 Wall Street analysts have issued 1-year price objectives for Repligen's stock. Their RGEN share price targets range from $165.00 to $210.00. On average, they predict the company's stock price to reach $189.55 in the next twelve months. This suggests a possible upside of 22.6% from the stock's current price.
View analysts price targets for RGEN or view top-rated stocks among Wall Street analysts.

Repligen's stock was trading at $169.31 on January 1st, 2023. Since then, RGEN shares have decreased by 8.7% and is now trading at $154.55.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024.
View our RGEN earnings forecast.

Repligen Co. (NASDAQ:RGEN) released its quarterly earnings data on Tuesday, October, 31st. The biotechnology company reported $0.23 earnings per share for the quarter, topping analysts' consensus estimates of $0.14 by $0.09. The biotechnology company had revenue of $141.20 million for the quarter, compared to the consensus estimate of $140.68 million. Repligen had a net margin of 17.29% and a trailing twelve-month return on equity of 6.08%. The company's revenue was down 29.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.77 EPS.

ETFs with the largest weight of Repligen (NASDAQ:RGEN) stock in their portfolio include Franklin Genomic Advancements ETF (HELX), Invesco Biotechnology & Genome ETF (PBE), BlackRock Future Innovators ETF (BFTR), Fidelity Disruptive Medicine ETF (FMED), VanEck Biotech ETF (BBH), Nuveen ESG Mid-Cap Growth ETF (NUMG), BNY Mellon Innovators ETF (BKIV) and Invesco ESG NASDAQ Next Gen 100 ETF (QQJG).

Repligen updated its FY23 earnings guidance on Tuesday, October, 31st. The company provided earnings per share guidance of $1.70-1.76 for the period, compared to the consensus EPS estimate of $1.74. The company issued revenue guidance of $635-645 million, compared to the consensus revenue estimate of $644.49 million.

13 employees have rated Repligen Chief Executive Officer Tony J. Hunt on Glassdoor.com. Tony J. Hunt has an approval rating of 52% among the company's employees. This puts Tony J. Hunt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Repligen investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Block (SQ), Advanced Micro Devices (AMD), DocuSign (DOCU), Walt Disney (DIS), Netflix (NFLX), Tesla (TSLA) and ServiceNow (NOW).

Repligen's stock is owned by many different retail and institutional investors. Top institutional shareholders include Sands Capital Management LLC (2.81%), Artisan Partners Limited Partnership (2.79%), Wellington Management Group LLP (2.50%), Bank of New York Mellon Corp (2.14%), Ameriprise Financial Inc. (2.07%) and Impax Asset Management Group plc (1.74%). Insiders that own company stock include Anthony Hunt, Christine Gebski, James Bylund, Jon Snodgres, Karen A Dawes, Karen A Dawes, Manner Carrie Eglinton, Martin D Madaus, Nicolas Barthelemy, Ralf Kuriyel and Thomas F Ryan Jr.
View institutional ownership trends.

Shares of RGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.